# 神経バイオマーカー市場

> 神経バイオマーカー市場調査報告書 アプリケーション別（アルツハイマー病、パーキンソン病、多発性硬化症、脳卒中、てんかん）、タイプ別（遺伝子バイオマーカー、プロテオミクスバイオマーカー、メタボロミクスバイオマーカー、イメージングバイオマーカー）、エンドユーザー別（製薬会社、臨床検査室、研究機関、CRO）、技術別（バイオ分子分析、イメージング技術、ゲノム配列決定、プロテオミクス）、地域別（北米、ヨーロッパ、南米、アジア太平洋、中東およびアフリカ） - 2035年までの予測。

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.24%
- **2024:** $ 5.04 Billion
- **2025:** $ 5.3 Billion
- **2035:** $ 8.83 Billion
- **Key Players:** Roche (CH), AbbVie(US), Biogen (US), Eli Lilly (US), Novartis (CH), Amgen (US), Merck (DE), Pfizer (US), AstraZeneca (GB)

**Report ID:** MRFR/HC/32076-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** September 17, 2026

**URL:** https://www.marketresearchfuture.com/reports/neurological-biomarker-market-33914

---

## Market Summary

## **Neurological Biomarker Market Overview**

As per MRFR analysis, the Neurological Biomarker Market Size was estimated at 5.04 (USD Billion) in 2024. The Neurological Biomarker Market Industry is expected to grow from 5.30 (USD Billion) in 2025 to 8.39 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 5.24% during the forecast period (2025 - 2034).

### **Key Neurological Biomarker Market Trends Highlighted**

The Global Neurological Biomarker Market is experiencing significant growth driven by the rising prevalence of neurological disorders and advancements in biomarker discovery technologies. There is an increasing demand for precise diagnostic tools and therapeutic strategies that can lead to early detection and better management of conditions such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Increased awareness about neurological diseases and the importance of biomarkers is helping to propel this market forward. Additionally, the emphasis on personalized medicine is fueling investment in research and development, leading to the advent of novel biomarkers that can improve patient outcomes.

Opportunities in the market arise from the integration of artificial intelligence and machine learning in biomarker research.

These technologies can analyze vast amounts of data, revealing patterns that assist in identifying new biomarkers and enhancing diagnostic accuracy. Furthermore, collaborations among research institutions, diagnostic companies, and pharmaceutical firms can result in innovative solutions that capitalize on the need for effective biomarker-based tools in clinical settings. 

The growing trend of home healthcare and telemedicine also opens new avenues for the deployment of neurological biomarkers in remote patient monitoring.Recent trends indicate a focus on developing biomarkers that can track disease progression and response to therapy, which can provide healthcare professionals with essential information for treatment adjustments. The exploration of neuroimaging techniques and the utilization of blood-based biomarkers are also gaining traction, promising to enhance diagnostic capabilities. The market is witnessing a gradual shift toward non-invasive approaches, reflecting a broader industry trend aimed at improving patient comfort and compliance.

Overall, the Global Neurological Biomarker Market is poised for a transformative phase fueled by innovation, collaboration, and an evolving understanding of neurological diseases.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Neurological Biomarker Market Drivers**

### **Increasing Prevalence of Neurological Disorders**

The Global Neurological Biomarker Market Industry is experiencing substantial growth, primarily driven by the rising incidence of neurological disorders such as [Alzheimer's disease](../../../reports/alzheimers-disease-diagnostic-market-2149), Parkinson's disease, and multiple sclerosis. As the global population ages, the number of individuals affected by these debilitating conditions is on the rise, leading to an increased demand for early diagnosis and effective treatment options. Neurological biomarkers play a crucial role in this context, as they aid in identifying the presence of neural dysfunction at a molecular level.By facilitating early detection, biomarkers enable timely interventions, which can significantly enhance patient outcomes.

Additionally, advancements in genomic and proteomic technologies are unlocking new avenues for research and development in biomarker discovery, further expanding the scope of their application in clinical settings. As healthcare systems worldwide shift towards personalized medicine, the focus on understanding individual patient profiles through biomarkers is expected to grow, thus propelling the market for neurological biomarkers.Consequently, the need for innovative and precise diagnostic tools to manage neurological disorders paves the way for significant investments in the Global Neurological Biomarker Market Industry, ensuring continued advancements in the field.

### **Technological Advancements in Biomarker Discovery**

The Global Neurological Biomarker Market Industry is significantly benefitting from rapid technological advancements in biomarker discovery methodologies. Innovations in fields such as genomics, proteomics, and metabolomics are leading to the development of more sensitive and specific biomarkers. These technologies enable researchers to uncover new biomarkers that can predict disease onset, monitor disease progression, and evaluate treatment responses more effectively.As these advanced tools become integrated into clinical practice, they are expected to drastically improve the accuracy of neurological assessments, driving demand in the biomarker market.

### **Rise in Research and Development Activities**

The Global Neurological Biomarker Market Industry is witnessing a surge in research and development activities, fueled by an increased focus on neurological health. Government and private sector initiatives aimed at funding and supporting research projects related to biomarker identification and validation are playing a pivotal role in this growth. This not only aids in the discovery of new biomarkers for various neurological disorders but also encourages collaboration between academic institutions, biotech companies, and pharmaceutical firms.As research progresses, it is likely to lead to the introduction of novel biomarkers into the market, thereby enhancing diagnostic capabilities and treatment personalization for patients.

## **Neurological Biomarker Market Segment Insights**

### **Neurological Biomarker Market Application Insights**

The Global Neurological Biomarker Market segment focused on Applications has shown considerable growth and importance in the healthcare landscape as of 2023. With a total market revenue of 4.55 USD Billion, the Application segment is further divided into specific conditions such as Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Stroke, and Epilepsy.

Alzheimer's Disease currently holds a prominent position, valued at 1.5 USD Billion in 2023, and is projected to rise to 2.4 USD Billion by 2032, showcasing a significant demand for innovative diagnostics and therapies in tackling this neurodegenerative disorder. The prominence of this segment is largely attributed to the increasing prevalence of Alzheimer's, which is becoming a major public health concern, reflecting its popularity in the Global Neurological Biomarker Market data.

Similarly, the Parkinson's Disease segment holds a value of 0.9 USD Billion in 2023 and is expected to grow to 1.5 USD Billion by 2032. This growth signifies the escalating research and development efforts aimed at understanding and managing symptoms of Parkinson's, making it a significant area within the Global Neurological Biomarker Market statistics.

Multiple Sclerosis, valued at 0.8 USD Billion in 2023, is another critical segment showing projected growth to 1.2 USD Billion by 2032, emphasizing the need for biomarkers to improve diagnosis and treatment options, as this condition predominantly affects adolescents and young adults.

Meanwhile, Stroke is valued at 0.95 USD Billion in 2023 and is anticipated to reach 1.65 USD Billion by 2032, demonstrating its importance in urgent patient care and the necessity for rapid diagnostic tools.The stroke segment's growth is driven by an increasing number of stroke incidents globally, highlighting the urgent healthcare need it addresses.

Lastly, the Epilepsy segment, currently valued at 0.4 USD Billion and growing to 0.66 USD Billion by 2032, shows a more modest yet notable impact in the market. The significance of neurological biomarkers related to epilepsy lies in the development of personalized medicine approaches, particularly in determining treatment efficacy for patients.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Neurological Biomarker Market Type Insights**

The Global Neurological Biomarker Market is evolving rapidly, with a projected value of 4.55 billion USD in 2023, aimed to reach 7.21 billion USD by 2032. The market segmentation by Type includes Genetic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, and Imaging Biomarkers. Genetic Biomarkers play an essential role in the early detection of various neurological diseases and hold significant potential in personalized medicine. Proteomic Biomarkers are crucial for understanding the pathological processes and identifying potential therapeutic targets, thereby driving the market growth.Metabolomic Biomarkers contribute to insights about disease progression and can aid in monitoring treatment responses.

Imaging Biomarkers are also increasingly significant due to advancements in neuroimaging technologies, allowing for enhanced disease diagnosis and management.

The market growth is supported by rising incidences of neurological disorders, increasing demand for precise diagnostics, and advancements in biomarker discovery techniques. However, challenges such as high developmental costs and stringent regulatory requirements may impact progress.Overall, the diversification in the Global Neurological Biomarker Market segmentation points to a comprehensive landscape with ample opportunities for research and development in the coming years.

### **Neurological Biomarker Market End User Insights**

The Global Neurological Biomarker Market has demonstrated significant potential, with a market valuation of 4.55 billion USD in 2023, reflecting its growing importance across various end-user segments. In this market landscape, Pharmaceutical Companies play a crucial role as they utilize neurological biomarkers to enhance drug development processes for neurological disorders. Clinical Laboratories also significantly contribute, offering essential diagnostic services that leverage these biomarkers for accurate disease identification and management.Research Institutions are pivotal in advancing the Global Neurological Biomarker Market data, conducting studies that lead to innovative biomarker discoveries and applications.

Additionally, Contract Research Organizations (CROs) support the market by providing specialized services that enable efficient and effective clinical trials, essential for new drug approvals. 

As the market expands towards a projected value of 7.21 billion USD by 2032, trends such as increasing investments in neurodegenerative disease research and advancements in biomarker technology are driving growth.However, challenges, including regulatory hurdles and the need for standardization, can impact market dynamics despite the promising opportunities that persist in this evolving industry. Overall, the Global Neurological Biomarker Market segmentation reflects a diverse and robust ecosystem crucial for addressing neurological health challenges.

### **Neurological Biomarker Market Technology Insights**

The Global Neurological Biomarker Market, particularly within the Technology segment, is significantly shaping the diagnostics and treatment landscape. In 2023, the market was valued at 4.55 billion, reflecting a growing recognition of the importance of neurological biomarkers in understanding disorders.

This Technology segment encompasses various crucial aspects such as Biomolecular Analysis, which facilitates the identification of disease markers, and Imaging Techniques that enhance visual interpretations of neurological conditions.

Genomic Sequencing is another critical component underpinning personalized medicine by offering insights into genetic predispositions to neurological diseases.Proteomics plays a significant role as it supports the analysis of protein expressions associated with neurological disorders, providing insights that are critical for developing targeted therapies.

The integration of these technologies not only drives market growth but also enhances the overall understanding of complex neurological conditions, contributing to better patient outcomes. The market, with a projected valuation of 7.21 billion by 2032, indicates a robust expansion driven by innovations and the increasing prevalence of neurological disorders.

### **Neurological Biomarker Market Regional Insights**

The Global Neurological Biomarker Market has shown a diverse array of valuations across its regional segments, with North America leading significantly at a valuation of 2.1 USD Billion in 2023, expected to reach 3.3 USD Billion by 2032. This region dominates largely due to advanced healthcare infrastructure and increased investment in research.

Europe followed with a valuation of 1.2 USD Billion in 2023, projected to grow to 1.9 USD Billion, driven by rising awareness of neurological disorders and the need for innovative diagnostic solutions. The APAC region presents a market value of 0.85 USD Billion in 2023, anticipated to grow to 1.35 USD Billion, reflecting a growing focus on healthcare advancements in emerging economies.South America and MEA have comparatively lower valuations at 0.25 USD Billion and 0.15 USD Billion, respectively, in 2023, with expected increases to 0.4 USD Billion and 0.26 USD Billion by 2032.

However, these regions offer significant growth potential due to increasing healthcare investments and collaborative initiatives for research and development. Overall, regional disparities highlight the importance of tailored market strategies to capitalize on local growth opportunities within the Global Neurological Biomarker Market industry.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Neurological Biomarker Market Key Players and Competitive Insights**

The Global Neurological Biomarker Market is characterized by a diverse range of players who are leveraging advanced technologies and innovations to deliver next-generation diagnostic solutions. The market comprises numerous companies, both established and emerging, which are collectively focused on enhancing the understanding of neurological conditions through biomarker discovery and validation. Advanced research methodologies combined with sophisticated technology platforms have enabled these companies to foster substantial progress in identifying biomarkers associated with various neurological disorders.Siemens Healthineers stands out in the Global Neurological Biomarker Market with its strong technological infrastructure and commitment to research and development. 

The company has established a significant market presence through its advanced imaging and diagnostic solutions that cater specifically to neurological disorders. With an emphasis on accuracy and reliability, Siemens Healthineers has developed diagnostic technologies that aid in the early detection of conditions such as Alzheimer's disease and other neurodegenerative disorders.

Their dedication to innovation is demonstrated through ongoing partnerships and collaborations with healthcare providers and research institutions, allowing them to stay at the forefront of the evolving landscape in neurological biomarkers.AstraZeneca plays a crucial role within the Global Neurological Biomarker Market by focusing on the development of innovative therapeutics and companion diagnostics for neurological disorders.

The company's robust portfolio is complemented by its significant investment in research initiatives aimed at unlocking the complexities of neurological diseases through biomarker identification. AstraZeneca's collaboration with academic institutions and biotechnology firms enables it to enhance its capabilities in biomarker discovery, facilitating the development of targeted therapies and personalized treatment plans. The company's strengths include a strong emphasis on scientific exploration and a commitment to integrating biomarker research into clinical practice, which supports the drive toward precision medicine.

### **Key Companies in the Neurological Biomarker Market Include**

- [Siemens Healthineers](https://www.siemens-healthineers.com/laboratory-diagnostics/assays-by-diseases-conditions/neurology-assays)
- AstraZeneca
- GSK
- Eli Lilly and Company
- Abbott Laboratories
- Medtronic
- Takeda Pharmaceutical
- Thermo Fisher Scientific
- Merck Group
- Pfizer
- Biogen
- Johnson and  Johnson
- Roche
- Novartis
- Amgen

## Neurological Biomarker Market Industry Developments

- **Q2 2024: Quanterix Launches Simoa® p-Tau 217 Advantage V2 Kit to Advance Alzheimer’s Disease Research** Quanterix announced the launch of its Simoa® p-Tau 217 Advantage V2 Kit, a next-generation neurological biomarker assay designed to improve the detection of Alzheimer’s disease pathology in blood samples.
- **Q2 2024: C2N Diagnostics Announces CE Mark for PrecivityAD2™ Blood Test for Alzheimer’s Disease** C2N Diagnostics received CE Mark approval for its PrecivityAD2™ blood test, enabling its commercial launch in Europe for the detection of Alzheimer’s disease biomarkers.
- **Q2 2024: Alto Neuroscience Raises $45 Million in Series C Financing to Advance Precision Psychiatry Platform** Alto Neuroscience secured $45 million in Series C funding to accelerate the development of its biomarker-driven platform for neurological and psychiatric disorders.
- **Q1 2024: Olink launches new neurology biomarker panel for high-throughput proteomics** Olink introduced a new neurology biomarker panel, expanding its high-throughput proteomics offering to support neurological disease research and drug development.
- **Q1 2024: Neurotrack and Quest Diagnostics Announce Strategic Partnership to Advance Early Detection of Cognitive Decline** Neurotrack and Quest Diagnostics formed a partnership to develop and commercialize digital and blood-based neurological biomarker tests for early detection of cognitive impairment.
- **Q2 2024: Diadem Receives FDA Breakthrough Device Designation for AlzoSure® Predict Blood Test for Alzheimer’s Disease** Diadem announced that its AlzoSure® Predict blood test for early detection of Alzheimer’s disease received Breakthrough Device Designation from the U.S. FDA.
- **Q2 2024: Amprion Receives FDA Breakthrough Device Designation for SYNTap Biomarker Test for Parkinson’s Disease** Amprion’s SYNTap Biomarker Test, designed to detect synucleinopathies such as Parkinson’s disease, was granted Breakthrough Device Designation by the FDA.
- **Q1 2024: Quanterix Appoints Masoud Toloue as Chief Executive Officer** Quanterix announced the appointment of Masoud Toloue as its new CEO, aiming to drive growth in the neurological biomarker sector.
- **Q2 2024: Cerveau Technologies and Eisai Enter Collaboration to Advance Tau PET Imaging Biomarker Research** Cerveau Technologies and Eisai announced a collaboration to advance research and development of tau PET imaging biomarkers for neurodegenerative diseases.
- **Q1 2024: Alzheon Announces $100 Million Series D Financing to Advance ALZ-801 and Biomarker Programs** Alzheon raised $100 million in Series D funding to support late-stage clinical development of ALZ-801 and expansion of its neurological biomarker programs.
- **Q2 2024: NeuroSense Therapeutics Receives FDA Orphan Drug Designation for PrimeC in ALS** NeuroSense Therapeutics received FDA Orphan Drug Designation for PrimeC, a therapy for ALS, which is supported by biomarker-driven clinical development.
- **Q1 2024: Alector and GSK Announce Strategic Collaboration to Develop Novel Neurodegeneration Biomarkers** Alector and GSK entered a strategic collaboration to develop and commercialize novel biomarkers for neurodegenerative diseases.

## **Neurological Biomarker Market Segmentation Insights**

### **Neurological Biomarker Market Application Outlook**

- Alzheimer's Disease
- Parkinson's Disease
- Multiple Sclerosis
- Stroke
- Epilepsy

### **Neurological Biomarker Market Type Outlook**

- Genetic Biomarkers
- Proteomic Biomarkers
- Metabolomic Biomarkers
- Imaging Biomarkers

### **Neurological Biomarker Market End User Outlook**

- Pharmaceutical Companies
- Clinical Laboratories
- Research Institutions
- CROs

### **Neurological Biomarker Market Technology Outlook**

- Biomolecular Analysis
- Imaging Techniques
- Genomic Sequencing
- Proteomics

### **Neurological Biomarker Market Regional Outlook**

- North America
- Europe
- South America
- Asia-Pacific
- Middle East and Africa ** **

## Market Drivers

### 研究開発への投資の増加

神経バイオマーカー市場は、研究開発活動への投資の増加から恩恵を受けています。製薬会社や研究機関は、神経障害の診断と治療を支援する新しいバイオマーカーを探求するために、ますますリソースを割り当てています。この傾向は、臨床試験やバイオマーカーの検証研究に向けられた substantial funding によって証明されています。2023年には、神経学分野の R&D 支出が約300億米ドルに達したと報告されており、神経学研究の進展に対するコミットメントの高まりを反映しています。このような投資は、診断精度と治療効果を向上させる革新的なバイオマーカーを生み出す可能性が高く、神経バイオマーカー市場の成長を促進するでしょう。

### バイオマーカー技術の進展

バイオマーカーの発見と検証における技術革新は、神経バイオマーカー市場の風景を変革しています。ハイスループットスクリーニング法、次世代シーケンシング、先進的な画像技術の登場により、神経バイオマーカーを特定し、特徴づける能力が大幅に向上しました。これらの進展は、神経障害の迅速な特定に不可欠な、より正確で信頼性の高い診断ツールの開発を促進します。その結果、神経バイオマーカー市場では、患者の転帰を改善し、臨床ワークフローを効率化できる新しいバイオマーカーが続々と登場しています。バイオマーカー分析における人工知能と機械学習の統合は、この傾向をさらに強化し、業界の明るい未来を示唆しています。

### 個別化医療の需要の高まり

個別化医療へのシフトは、神経バイオマーカー市場に大きな影響を与えています。医療が一律のアプローチから離れるにつれて、個々の患者プロファイルに基づいて治療を調整することへの強調が高まっています。神経バイオマーカーは、特定の疾患サブタイプを特定し、治療反応を予測することを可能にすることで、このパラダイムシフトにおいて重要な役割を果たしています。神経学における個別化医療の市場は、今後数年間で10％以上の年平均成長率で成長することが予測されています。この傾向は、標的療法の開発におけるバイオマーカーの重要性を強調し、神経バイオマーカー市場内での需要を促進しています。

### 神経障害の増加する有病率

アルツハイマー病、パーキンソン病、及び多発性硬化症などの神経疾患の発生率の増加は、神経バイオマーカー市場の主要な推進要因です。最近の推計によると、これらの病状に影響を受ける人々の数は大幅に増加することが予測されており、アルツハイマー病だけでも2050年までに1400万人以上に影響を及ぼすとされています。この有病率の急増は、効果的な診断ツールと治療オプションの開発を必要とし、それによって神経バイオマーカーの需要が高まります。医療システムが増加する患者集団を管理しようとする中で、神経バイオマーカー市場は早期発見と個別化された治療戦略の必要性に駆動されて、 substantial growth を経験する可能性が高いです。

### バイオマーカー開発のための規制支援

規制機関は、バイオマーカーの開発と検証を支援する枠組みを提供することにより、神経バイオマーカーマーケットの成長を促進する重要な役割を果たしています。バイオマーカーの承認プロセスを迅速化することを目的とした取り組みは、製薬会社がこの分野に投資することを促しています。例えば、FDAは、薬剤開発および臨床試験におけるバイオマーカーの適格性を促進するプログラムを設立しました。この規制の支援は、新しいバイオマーカーの市場への導入を加速させるだけでなく、医療専門家の間でこれらのツールの信頼性を高めます。その結果、より多くの検証済みバイオマーカーが臨床使用のために利用可能になるにつれて、神経バイオマーカーマーケットは拡大する可能性があります。

## Future Outlook

神経バイオマーカー市場は、2024年から2035年にかけて5.24%のCAGRで成長する見込みであり、これは診断技術の進歩、神経障害の有病率の増加、そして医療への投資の増加によって推進されます。

**New opportunities:**

- ターゲット療法のための個別化バイオマーカーパネルの開発。
- バイオマーカー発見プロセスにおけるAI駆動の分析の統合。
- リモートバイオマーカー監視のための[テレヘルス](/ja/reports/telehealth-market-900)サービスの拡大。

2035年までに、神経バイオマーカー市場は堅調であり、 substantialな成長と革新を反映することが期待されています。

## Segment Insights

### 用途別：アルツハイマー病（最大）対 パーキンソン病（最も成長が早い）

神経バイオマーカー市場において、アルツハイマー病は、世界的に病気の有病率が上昇しているため、最大のシェアを持つ支配的なアプリケーションセグメントとして際立っています。それに続いて、パーキンソン病が勢いを増しており、認識の向上と診断の進展によって、最も成長しているセグメントとしての役割を反映しています。多発性硬化症、脳卒中、てんかんなどの他のアプリケーションも意味のあるシェアを持っていますが、現在はアルツハイマー関連のバイオマーカーに対する需要の大きさに影を潜めています。神経バイオマーカー市場の成長トレンドは、高齢化社会、バイオマーカー発見の進展、神経障害の早期診断への強調など、さまざまな要因によって推進されています。特にアルツハイマー病とパーキンソン病において、研究開発への投資が重要であり、継続的な革新が新しい検査オプションや治療法を促進し、生活の質を向上させ、体系的な医療の課題に対処しています。

アルツハイマー病（優性）対パーキンソン病（新興）

アルツハイマー病は神経バイオマーカー市場の基盤であり、診断および病気の進行状況のモニタリングに不可欠なさまざまなバイオマーカーを含んでいます。このセグメントは、早期発見の必要性に対する認識の高まりとともに、相当な研究資金の恩恵を受けています。アルツハイマーのバイオマーカーは確立されており、臨床医にとって信頼できる枠組みを提供しています。一方、パーキンソン病は新たなセグメントを代表しており、臨床試験やバイオマーカー技術の革新によって推進されています。このセグメントは、神経炎症と病気の進行との相関に焦点を当てており、集中的な研究開発の分野となっています。診断オプションがより洗練されるにつれて、パーキンソン病のバイオマーカーは神経変性研究で注目を集めており、確立されたアルツハイマーの指標を補完し、特化した治療戦略の緊急の必要性を明らかにしています。

### タイプ別：遺伝的バイオマーカー（最大）対画像バイオマーカー（最も成長が早い）

神経バイオマーカー市場は、遺伝子、プロテオミクス、メタボロミクス、イメージングバイオマーカーを含む多様なセグメントの価値分布を反映しています。これらの中で、遺伝子バイオマーカーは神経障害に対する遺伝的素因を特定する上での重要な役割により、最大の市場シェアを占めています。彼らは個別化治療計画の開発に広く利用されています。イメージングバイオマーカーは、現在は小さなセグメントですが、技術の進歩によりその精度と信頼性が向上し、臨床診断や研究における需要が増加しているため、急速に注目を集めています。

遺伝的バイオマーカー（優勢）対画像バイオマーカー（新興）

遺伝的バイオマーカーは、神経障害に対する遺伝的素因に関する重要な洞察を提供し、早期診断や個別化治療を支援する能力により、神経バイオマーカー市場で主導的な力を確立しています。一方、MRIやPETスキャンなどの最先端技術によって特徴づけられる画像バイオマーカーは、その非侵襲的な性質により、重要なプレーヤーとして浮上しています。脳内の変化をリアルタイムで可視化することへの関心の高まりや、画像分析における人工知能の統合が、彼らの急速な成長を促進しています。これらのダイナミクスは神経診断の風景を再形成しており、両者が患者の結果を向上させるために補完的な役割を果たしています。

### エンドユーザー別：製薬会社（最大）対臨床検査室（最も成長が早い）

神経バイオマーカー市場は、主に製薬会社、臨床検査室、研究機関、契約研究機関（CRO）を含む多様なエンドユーザーによって特徴付けられています。これらの中で、製薬会社はバイオマーカー開発における広範なリソースと能力を活用し、最大の市場シェアを占めています。一方、臨床検査室は急速に注目を集めており、神経バイオマーカーを採用することで診断提供を強化し、患者の転帰を改善しています。成長傾向は、製薬会社が革新的な薬剤発見と個別化医療に注力しており、神経バイオマーカーの需要を推進していることを示しています。対照的に、臨床検査室は技術の進歩と神経障害に対する認識の高まりから恩恵を受けており、この進化する市場における重要なプレーヤーとしての地位を確立しています。研究機関とCROも成長に寄与していますが、主にコラボレーションや研究イニシアチブに焦点を当てており、成長のペースは遅いです。

製薬会社（支配的）対臨床検査室（新興）

製薬会社は現在、神経バイオマーカー市場において支配的な力を持ち、膨大な財政資源と研究開発能力を活用してターゲット療法を開発しています。彼らの確立された地位は、臨床試験や規制承認においてリードすることを可能にし、競争上の優位性を与えています。それに対して、臨床検査室は診断プロセスにおける役割がますます重要になる中で、重要なプレーヤーとして浮上しています。技術の進歩に伴い、これらの検査室は神経疾患に対するより包括的な検査を提供するためにサービスを拡大しています。個別化医療への推進もこの変化に影響を与えており、臨床検査室はカスタマイズされたソリューションを提供するように適応しています。これらのセグメントは、確立された企業と新興企業が共存し、繁栄するダイナミックな風景を示しています。

### 技術別：バイオ分子分析（最大）対イメージング技術（最も成長している）

神経バイオマーカー市場は、さまざまな技術革新によって大きく影響を受けています。バイオ分子分析は、その確立された方法論と神経障害の診断における広範な応用により、このセグメントでの市場シェアを支配しています。病気の特定とモニタリングのためにさまざまなバイオ分子を利用することが、その地位を強化し、神経研究および臨床応用において重要なセグメントとなっています。イメージング技術は、現在は小さなシェアを持っていますが、高度なMRI技術や機能的イメージングなどの革新により急速に成長しており、神経疾患の診断と治療計画の改善が期待されています。

バイオ分子分析（主流）対イメージング技術（新興）

バイオ分子分析は、生物学的分子を用いて神経疾患の特定と評価を行うことが特徴です。その優位性は、確立されたプロトコルと臨床現場での受け入れに起因しています。この分野は、神経状態に関する洞察を効果的に提供するために、タンパク質、酵素、核酸を含むさまざまな技術を網羅しています。一方、イメージング技術は、MRIやPETスキャンなどの革新的な技術を誇り、脳の機能を理解し、障害を特定する上で重要になりつつあります。まだ発展途上ではありますが、正確な診断に対する需要の高まりと、より効率的なイメージングソリューションへの道を開く継続的な技術革新により、急速に注目を集めています。

## Regional Market Share Analysis

### North America : Leading Innovation and Research

North America is the largest market for neurological biomarkers, holding approximately 45% of the global share. The region benefits from advanced healthcare infrastructure, significant R&D investments, and a growing prevalence of neurological disorders. Regulatory support from agencies like the FDA accelerates the approval of innovative biomarker tests, driving market growth. The increasing focus on personalized medicine and early diagnosis further fuels demand for these biomarkers. The United States is the primary contributor to this market, with key players such as Roche, AbbVie, and Biogen leading the charge. The competitive landscape is characterized by a mix of established pharmaceutical giants and emerging biotech firms. Canada also plays a significant role, with a growing emphasis on research collaborations and clinical trials, enhancing the overall market dynamics.

### Europe : Regulatory Support and Growth

Europe is the second-largest market for neurological biomarkers, accounting for approximately 30% of the global share. The region's growth is driven by increasing investments in healthcare and a rising incidence of neurological diseases. Regulatory frameworks, such as the European Medicines Agency's guidelines, facilitate the development and approval of innovative biomarkers, enhancing market accessibility. The focus on precision medicine and patient-centric approaches is also a significant growth driver. Leading countries in this region include Germany, France, and the UK, where major pharmaceutical companies like Merck and AstraZeneca are actively involved in biomarker research. The competitive landscape is robust, with numerous collaborations between academia and industry. The presence of well-established healthcare systems and funding for research initiatives further strengthens the market position of neurological biomarkers in Europe.

### Asia-Pacific : Rapidly Growing Market Potential

Asia-Pacific is witnessing rapid growth in the neurological biomarker market, holding approximately 20% of the global share. The region's expansion is fueled by increasing healthcare expenditure, a rising aging population, and a growing awareness of neurological disorders. Countries like China and India are investing heavily in healthcare infrastructure and research, which is expected to drive demand for biomarkers. Regulatory bodies are also becoming more supportive of innovative diagnostic solutions, further catalyzing market growth. China is the largest market in this region, with significant contributions from local biotech firms and multinational corporations. India is emerging as a key player, focusing on research and development in neurological biomarkers. The competitive landscape is evolving, with collaborations between local and international companies enhancing innovation and market reach. The increasing prevalence of neurological diseases in these countries is expected to further boost market dynamics.

### Middle East and Africa : Untapped Market Opportunities

The Middle East and Africa region is gradually emerging in the neurological biomarker market, currently holding about 5% of the global share. The growth is driven by increasing healthcare investments and a rising prevalence of neurological disorders. Governments are beginning to recognize the importance of biomarkers in diagnostics, leading to supportive regulatory frameworks. The region's diverse healthcare needs present significant opportunities for market expansion, particularly in countries like South Africa and the UAE. South Africa is the leading market in this region, with a growing focus on research and development in neurological health. The competitive landscape is characterized by a mix of local and international players, with increasing collaborations aimed at enhancing diagnostic capabilities. The presence of key players is still developing, but the potential for growth is substantial as awareness and healthcare access improve across the region.

## Competitive Benchmarking

The Neurological Biomarker Market is currently characterized by a dynamic competitive landscape, driven by increasing demand for early diagnosis and personalized treatment options for neurological disorders. Key players such as Roche (CH), AbbVie (US), and Biogen (US) are strategically positioned to leverage their extensive research capabilities and innovative product pipelines. Roche (CH) focuses on integrating advanced diagnostics with therapeutic solutions, while AbbVie (US) emphasizes partnerships to enhance its biomarker discovery capabilities. Biogen (US), on the other hand, is heavily investing in digital health technologies to improve patient engagement and data collection, thereby shaping a competitive environment that prioritizes innovation and patient-centric approaches.The market structure appears moderately fragmented, with several players vying for market share through localized manufacturing and optimized supply chains. Companies are increasingly adopting tactics that enhance operational efficiency and reduce time-to-market for new biomarker tests. This competitive structure allows for a diverse range of offerings, although the influence of major players remains significant in setting industry standards and driving technological advancements.
In August Roche (CH) announced a collaboration with a leading AI firm to develop predictive models for Alzheimer’s disease biomarkers. This strategic move is likely to enhance Roche's capabilities in early diagnosis, positioning the company at the forefront of innovation in the neurological biomarker space. The integration of AI into biomarker development could streamline research processes and improve the accuracy of diagnostic tools, thereby reinforcing Roche's competitive edge.
In September AbbVie (US) expanded its partnership with a prominent academic institution to advance research in neurodegenerative diseases. This collaboration is expected to facilitate the discovery of novel biomarkers, which could lead to breakthroughs in treatment options. By aligning with academic leaders, AbbVie is not only enhancing its research portfolio but also fostering an ecosystem of innovation that may yield significant advancements in the field.
In July Biogen (US) launched a new digital platform aimed at enhancing patient monitoring and data collection for neurological disorders. This initiative reflects Biogen's commitment to integrating technology into its operations, potentially improving patient outcomes and engagement. The platform is designed to collect real-time data, which could be invaluable for refining biomarker development and tailoring treatment strategies to individual patient needs.
As of October the competitive trends in the Neurological Biomarker Market are increasingly influenced by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are becoming more prevalent, as companies recognize the value of collaborative innovation in addressing complex neurological challenges. Looking ahead, it appears that competitive differentiation will increasingly hinge on technological advancements and the reliability of supply chains, rather than solely on price. This shift suggests a future where innovation and strategic partnerships will be paramount in navigating the evolving landscape of the neurological biomarker market.

## Recent News & Developments

- **Q2 2024: Quanterix Launches Simoa® p-Tau 217 Advantage V2 Kit to Advance Alzheimer’s Disease Research** Quanterix announced the launch of its Simoa® p-Tau 217 Advantage V2 Kit, a next-generation neurological biomarker assay designed to improve the detection of Alzheimer’s disease pathology in blood samples.
- **Q2 2024: C2N Diagnostics Announces CE Mark for PrecivityAD2™ Blood Test for Alzheimer’s Disease** C2N Diagnostics received CE Mark approval for its PrecivityAD2™ blood test, enabling its commercial launch in Europe for the detection of Alzheimer’s disease biomarkers.
- **Q2 2024: Alto Neuroscience Raises $45 Million in Series C Financing to Advance Precision Psychiatry Platform** Alto Neuroscience secured $45 million in Series C funding to accelerate the development of its biomarker-driven platform for neurological and psychiatric disorders.
- **Q1 2024: Olink launches new neurology biomarker panel for high-throughput proteomics** Olink introduced a new neurology biomarker panel, expanding its high-throughput proteomics offering to support neurological disease research and drug development.
- **Q1 2024: Neurotrack and Quest Diagnostics Announce Strategic Partnership to Advance Early Detection of Cognitive Decline** Neurotrack and Quest Diagnostics formed a partnership to develop and commercialize digital and blood-based neurological biomarker tests for early detection of cognitive impairment.
- **Q2 2024: Diadem Receives FDA Breakthrough Device Designation for AlzoSure® Predict Blood Test for Alzheimer’s Disease** Diadem announced that its AlzoSure® Predict blood test for early detection of Alzheimer’s disease received Breakthrough Device Designation from the U.S. FDA.
- **Q2 2024: Amprion Receives FDA Breakthrough Device Designation for SYNTap Biomarker Test for Parkinson’s Disease** Amprion’s SYNTap Biomarker Test, designed to detect synucleinopathies such as Parkinson’s disease, was granted Breakthrough Device Designation by the FDA.
- **Q1 2024: Quanterix Appoints Masoud Toloue as Chief Executive Officer** Quanterix announced the appointment of Masoud Toloue as its new CEO, aiming to drive growth in the neurological biomarker sector.
- **Q2 2024: Cerveau Technologies and Eisai Enter Collaboration to Advance Tau PET Imaging Biomarker Research** Cerveau Technologies and Eisai announced a collaboration to advance research and development of tau PET imaging biomarkers for neurodegenerative diseases.
- **Q1 2024: Alzheon Announces $100 Million Series D Financing to Advance ALZ-801 and Biomarker Programs** Alzheon raised $100 million in Series D funding to support late-stage clinical development of ALZ-801 and expansion of its neurological biomarker programs.
- **Q2 2024: NeuroSense Therapeutics Receives FDA Orphan Drug Designation for PrimeC in ALS** NeuroSense Therapeutics received FDA Orphan Drug Designation for PrimeC, a therapy for ALS, which is supported by biomarker-driven clinical development.
- **Q1 2024: Alector and GSK Announce Strategic Collaboration to Develop Novel Neurodegeneration Biomarkers** Alector and GSK entered a strategic collaboration to develop and commercialize novel biomarkers for neurodegenerative diseases.

## Report Scope

| MARKET SIZE 2024 | 5.036(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 5.3(USD Billion) |
| MARKET SIZE 2035 | 8.833(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.24% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Roche (CH), AbbVie (US), Biogen (US), Eli Lilly (US), Novartis (CH), Amgen (US), Merck (DE), Pfizer (US), AstraZeneca (GB) |
| Segments Covered | Applications, Types, End Users, Technology, Regional |
| Key Market Opportunities | Advancements in precision medicine enhance diagnostic capabilities within the Neurological Biomarker Market. |
| Key Market Dynamics | Rising demand for early diagnosis drives innovation in neurological biomarker development and regulatory adaptations. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: 2035年までの神経バイオマーカー市場の予測市場評価額はどのくらいですか？**
A: 神経バイオマーカー市場は、2035年までに約88.33億USDに達すると予測されています。

**Q: 2024年の神経バイオマーカー市場の市場評価はどのくらいでしたか？**
A: 2024年、神経バイオマーカー市場は50.36億USDの価値がありました。

**Q: 神経バイオマーカー市場の予測期間2025年から2035年のCAGRはどのくらいですか？**
A: 神経バイオマーカー市場の予測期間2025年から2035年のCAGRは5.24%です。

**Q: 神経バイオマーカー市場で重要なプレーヤーと見なされる企業はどれですか？**
A: 神経バイオマーカー市場の主要なプレーヤーには、ロシュ、アッヴィ、バイオジェン、イーライリリー、ノバルティス、アムジェン、メルク、ファイザー、アストラゼネカが含まれます。

**Q: 2035年までの神経バイオマーカー市場におけるアルツハイマー病の予測評価額はどのようになりますか？**
A: アルツハイマー病の神経バイオマーカー市場における予測評価額は、2035年までに15億米ドルから25億米ドルに上昇する見込みです。

**Q: 遺伝子バイオマーカーは、プロテオミクスバイオマーカーと比較して市場評価の点でどのように異なりますか？**
A: 遺伝子バイオマーカーは1.509億米ドルから2.646億米ドルに成長すると予測されており、プロテオミクスバイオマーカーは1.007億米ドルから1.749億米ドルに増加すると期待されています。

**Q: 2035年までの神経バイオマーカー市場における臨床検査室の予想市場規模はどのくらいですか？**
A: 臨床検査室の市場規模は、2035年までに10.08億USDから17.5億USDに成長すると予想されています。

**Q: 神経バイオマーカー市場に影響を与えると予想される技術的進歩は何ですか？**
A: バイオ分子分析、イメージング技術、ゲノムシーケンシング、プロテオミクスにおける技術革新は、市場の成長を促進する可能性が高く、2035年までに評価額が大幅に増加することが予測されています。

**Q: 2035年までの脳卒中関連バイオマーカーの市場規模はどのくらいになると予測されていますか？**
A: 脳卒中関連バイオマーカーの市場規模は、2035年までに9億USDから15億USDに増加する見込みです。

**Q: 神経バイオマーカー市場の成長は、異なるアプリケーション間でどのように比較されますか？**
A: 神経バイオマーカー市場は、アプリケーションごとに異なる成長を示しており、アルツハイマー病とパーキンソン病は2035年までに最も高い評価を受けると予測されています。


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/neurological-biomarker-market-33914*